Senesco Technologies, Inc. (SNT) Expands Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Today, Senesco Technologies reported that the clinical trial of SNS01-T has been expanded to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The company has enrolled the first patient with DLBCL in cohort 2; that patient received the first dose last week. Like multiple myeloma, DLBCL and MCL are B-cell cancers that SNS01-T was designed to treat. Senesco submitted a protocol amendment to the United States Food and Drug Administration in August to open the study to patients suffering with these non-Hodgkin’s B-cell lymphomas. Having the ability to include other hematological cancers broadens Senesco’s results and can…